CD274 and non-small cell lung carcinoma: These data are consistent with the evidence [KEYNOTE-001 trial/pembrolizumab (anti-PDL1) treatment] (41, 42) that high expression of PDL1, a classical immune suppressive check point molecule was associated with better survival among pembrolizumab-treated NSCLC and melanoma patients.